MENU
+Compare
RANI
Stock ticker: NASDAQ
AS OF
Dec 18, 04:59 PM (EDT)
Price
$1.35
Change
-$0.11 (-7.53%)
Capitalization
48.63M

RANI Rani Therapeutics Holdings Forecast, Technical & Fundamental Analysis

Industry Biotechnology
RANI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
a Summary for RANI with price predictions
Dec 17, 2024

RANI's RSI Oscillator remains in oversold zone for 3 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 20 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RANI advanced for three days, in of 191 cases, the price rose further within the following month. The odds of a continued upward trend are .

RANI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 15, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on RANI as a result. In of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for RANI turned negative on November 15, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 30 similar instances when the indicator turned negative. In of the 30 cases the stock turned lower in the days that followed. This puts the odds of success at .

RANI moved below its 50-day moving average on November 14, 2024 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for RANI crossed bearishly below the 50-day moving average on November 20, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RANI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for RANI entered a downward trend on December 17, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (14.409) is normal, around the industry mean (14.664). P/E Ratio (0.000) is within average values for comparable stocks, (87.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.783). RANI has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (0.000) is also within normal values, averaging (260.687).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. RANI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RANI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
RANI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

RANI is expected to report earnings to rise 8.33% to -25 cents per share on March 19

Rani Therapeutics Holdings RANI Stock Earnings Reports
Q4'24
Est.
$-0.26
Q3'24
Beat
by $0.05
Q2'24
Beat
by $0.08
Q1'24
Missed
by $0.01
Q4'23
Beat
by $0.11
The last earnings report on November 14 showed earnings per share of -23 cents, beating the estimate of -28 cents. With 1.12M shares outstanding, the current market capitalization sits at 48.63M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
2051 Ringwood Avenue
Phone
+1 408 457-3700
Employees
140
Web
https://www.ranitherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
INUV0.380.03
+8.42%
Inuvo
HMC25.260.24
+0.96%
Honda Motor Co Ltd
LILA6.63N/A
N/A
Liberty Latin America Ltd
SPXC153.03-3.34
-2.14%
SPX Technologies
POET4.44-0.14
-3.06%
POET Technologies

RANI and Stocks

Correlation & Price change

A.I.dvisor tells us that RANI and DRUG have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RANI and DRUG's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RANI
1D Price
Change %
RANI100%
-8.18%
DRUG - RANI
31%
Poorly correlated
+2.40%
UBX - RANI
31%
Poorly correlated
-5.56%
FATE - RANI
28%
Poorly correlated
-6.00%
BLUE - RANI
27%
Poorly correlated
+14.85%
SNTI - RANI
26%
Poorly correlated
+0.78%
More